Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes
Nicholas A. Marston, Erin Ann Bohula, Ajay K. Bhatia, Gaetano M. De Ferrari et autres
Importance: Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors for cardiovascular event reduction has largely been reserved for patients with significant atherosclerosis. Objective: To investigate whether evolocumab could prevent a first major cardiovascular event …
us, tr, it, ca, br, gb, au, es, de (code pays fourni par la source)
20 citations
JAMA